AB Science will participate in the Biomed Forum investors conference

Company Overview - AB Science is a pharmaceutical company founded in 2001, specializing in the research, development, and commercialization of protein kinase inhibitors (PKIs) [2] - The company targets diseases with high unmet medical needs, including those that are often lethal or rare and refractory to previous treatments [2] Product Development - AB Science has developed a proprietary portfolio of molecules, with its lead compound, masitinib, already registered for veterinary medicine and under development for human medicine in various fields such as oncology, neurological diseases, inflammatory diseases, and viral diseases [3] Upcoming Events - AB Science's management team will participate in the Biomed Forum, a conference for institutional investors, scheduled for February 4, 2025, in Paris [1]